Concepedia

Jasmine Hewlett

JH

4

Publications

1K

Citations

4

H-Index

1999

Active since

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

Alnylam Pharmaceuticals (United States)

Wellcome Trust

Yale University

Jasmine Hewlett is an author at Alexion Pharmaceuticals (United States) specializing in medicine and pharmacology.

Top concepts

Publications per year

1999–2020

4

Publications

4

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

, , +3

Double‐Blind Placebo‐Controlled Study of Concurrent Administration of Albendazole and Praziquantel in Schoolchildren with Schistosomiasis and Geohelminths

G R Olds, Charles H. King, Jasmine Hewlett et al. · The Journal of Infectious Diseases · 1999 · 155 citations · Full text

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text

Rows per page

1–4 of 4